Method to detect RNA biomarkers

The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1 -yl)methyl) benzamide, during the clinica...

Full description

Saved in:
Bibliographic Details
Main Authors FOSSATI, GIANLUCA, RIPAMONTI, CHIARA, STEINKUEHLER, CHRISTIAN
Format Patent
LanguageChinese
English
Published 16.10.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1 -yl)methyl) benzamide, during the clinical treatment of patients affected by cancer. More in particular, the invention refers to the analysis of the gene expression's variation of specific biomarkers in human monocytes, as "gene expression signatures", in a method to evaluate the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1 -yl)methyl)benzamide.
Bibliography:Application Number: TW202211143736